Travere Therapeutics, Inc. (TVTX) is held by 3 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds opening new positions and 2 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $79.5M sold). Latest close $50.24 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Oct 15, 2026 · Congress to Nov 16, 2026.
Perceptive Advisors · OrbiMed Advisors · Polen Capital Management — 3 tracked funds hold TVTX. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 44 sales ($79.5M). Insider trading
Praxis Precision Medicines, Inc. (PRAX) · Protagonist Therapeutics, Inc (PTGX) · Axsome Therapeutics, Inc. (AXSM) · Guardant Health, Inc. (GH) · Natera, Inc. (NTRA) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Perceptive Advisors | 3.20% | 3,752,574 | TRIMMED (-9.4%) Q3 filed Nov 16 |
| OrbiMed Advisors | 0.27% | 253,000 | NEW Q3 filed Nov 16 |
| Polen Capital Management | 0.02% | 34,315 | NEW Q3 filed Nov 13 |
| RA Capital Management | — | — | EXITED |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -9.3% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 317 of 8,857 filers |
| Long-only filers among them | 316 |
| Change vs 2026 Q1 | +62 net · 305 entered · 243 exited |
| Shares reported, all filers | 105,087,909 |
| Reported value, all filers | $5.9B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | $490.7M |
| Net income · FY2025 | $-25.5M |
| Total assets · FY2025 | $605.2M |
| Shares outstanding | 94,261,082 |
| Market cap (at latest close) | $4.7B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 30, 2026.
| Shares short · Oct 15, 2026 | 10,913,583 |
| Share of shares outstanding | 11.58% |
| Days to cover | 5.24 |
Shares short at recent settlements — Jul 31, 2026: 11.7M · Aug 14, 2026: 11.9M · Aug 31, 2026: 12.0M · Sep 15, 2026: 13.0M · Sep 30, 2026: 12.7M · Oct 15, 2026: 10.9M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 30, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 78K · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 30, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 44 sales by 8 insiders ($79.5M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 128,065 | $52.97 | $6.8M | SEC filing |
| Oct 15, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 37,270 | $54.20 | $2.0M | SEC filing |
| Oct 15, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 78,400 | $55.02 | $4.3M | SEC filing |
| Sep 17, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sell | 8,282 | $65.07 | $538.9K | SEC filing |
| Sep 17, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 101,691 | $64.59 | $6.6M | SEC filing |
| Sep 17, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 6,802 | $64.95 | $441.8K | SEC filing |
| Sep 16, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sell | 93,604 | $63.25 | $5.9M | SEC filing |
| Sep 16, 2026 | Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sell | 79,113 | $63.65 | $5.0M | SEC filing |
| Sep 16, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 99,716 | $63.26 | $6.3M | SEC filing |
| Sep 16, 2026 | Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | 96,125 | $63.64 | $6.1M | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | ERIC DUBE | Director, Officer | 108,493 | $6.9M | Sep 17, 2026 | SEC filing |
| Sep 17, 2026 | PETER HEERMA | Officer | 8,282 | $525.7K | Sep 17, 2026 | SEC filing |
| Sep 16, 2026 | WILLIAM ROTE | Officer | 112,850 | $7.1M | Sep 16, 2026 | SEC filing |
| Sep 16, 2026 | PETER HEERMA | Officer | 172,717 | $10.8M | Sep 16, 2026 | SEC filing |
| Sep 16, 2026 | ERIC DUBE | Director, Officer | 195,841 | $12.2M | Sep 16, 2026 | SEC filing |
| Sep 15, 2026 | SANDRA CALVIN | Officer | 5,375 | $353.6K | Sep 15, 2026 | SEC filing |
| Sep 15, 2026 | CHRISTOPHER CLINE | Officer | 50,508 | $3.3M | Sep 15, 2026 | SEC filing |
| Sep 15, 2026 | ELIZABETH REED | Officer | 39,576 | $2.6M | Sep 15, 2026 | SEC filing |
| Sep 15, 2026 | ERIC DUBE | Director, Officer | 95,666 | $6.3M | Sep 15, 2026 | SEC filing |
| Sep 15, 2026 | PETER HEERMA | Officer | 102,190 | $6.7M | Sep 15, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Armistice Capital, LLC | SC 13G/A | 1,572,539 | 1.7% | Jun 30, 2026 | SEC filing |
| Aug 12, 2026 | BANK OF AMERICA CORP /DE/ | SC 13G | 5,439,155 | 5.8% | Jun 30, 2026 | SEC filing |
| Aug 7, 2026 | STATE STREET CORPORATION | SC 13G | 4,256,224 | 4.6% | Jun 30, 2026 | SEC filing |
| Aug 6, 2026 | FMR LLC | SC 13G/A | 7,142,482.22 | 7.7% | Jun 30, 2026 | SEC filing |
| May 15, 2026 | Armistice Capital, LLC | SC 13G | 4,897,417 | 5.3% | Mar 31, 2026 | SEC filing |
| Apr 30, 2026 | Vanguard Capital Management | SC 13G | 4,699,424 | 5.1% | Mar 31, 2026 | SEC filing |
| Mar 27, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Feb 17, 2026 | Perceptive Advisors LLC | SC 13G/A | 4,278,180 | 4.8% | Dec 31, 2025 | SEC filing |
| Feb 17, 2026 | Armistice Capital, LLC | SC 13G/A | 3,763,891 | 4.2% | Dec 31, 2025 | SEC filing |
| Feb 13, 2026 | Macquarie Group Limited | SC 13G/A | 0 | 0.0% | Dec 31, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 144 Lobbying Disclosure Act filings named this company as client, 2016–2026; most common issues: Health Issues (134), Pharmacy (127), Medicare/Medicaid (119).
Federal contracts: $2.8M in obligated amounts, fiscal years 2021–2026.
| Fiscal year | Obligated amount |
|---|---|
| FY2021 | $211.5K |
| FY2022 | $621.4K |
| FY2023 | $640.4K |
| FY2024 | $656.7K |
| FY2025 | $334.9K |
| FY2026 | $323.9K |
Largest awards collected
| Award ID | Agency | Amount | Start |
|---|---|---|---|
| 36C25024P0081 | Department of Veterans Affairs | $236.5K | Oct 10, 2023 |
| 36C25023P0906 | Department of Veterans Affairs | $236.5K | Mar 24, 2023 |
| 36C25023P0088 | Department of Veterans Affairs | $236.5K | Oct 14, 2022 |
| 36C25022P0844 | Department of Veterans Affairs | $236.5K | Apr 1, 2022 |
| 36C25025P0025 | Department of Veterans Affairs | $212.6K | Oct 1, 2024 |
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
Red Flags
· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10
Key figures
· Distress Risk (Altman Z″) — Z″-Score: -5.38 · Working capital / assets: 0.46 · Retained earnings / assets: -2.43 · EBIT / assets: -0.10 · Equity / liabilities: 0.23
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
Also held by the tracked funds that hold TVTX — ranked by lift, the co-holding pattern described in Methodology: Praxis Precision Medicines, Inc. (PRAX) · Protagonist Therapeutics, Inc (PTGX) · Axsome Therapeutics, Inc. (AXSM) · Guardant Health, Inc. (GH) · Natera, Inc. (NTRA) · BOSTON SCIENTIFIC CORP (BSX) · INTUITIVE SURGICAL INC (ISRG).
| Filed | Items | Source |
|---|---|---|
| Nov 2, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Sep 21, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 4, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Praxis Precision Medicines, Inc. (PRAX) · Track Record: how the signals scored · Practice timing on TVTX
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.